- Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809–818. doi:10.1056/NEJMoa1703068.
- Kruse-Jarres R, Callaghan MU, Croteau SE, et al. Surgical experience in two multicenter, open-label phase 3 studies of emicizumab in persons with hemophilia A with inhibitors (HAVEN 1 and HAVEN 2). Blood. 2017;130:S89.
- Seaman CD, Ragni MV. Emicizumab use in major orthopedic surgery. Blood Adv. 2019;3(11):1722–1724. doi:10.1182/bloodadvances.2019000228.
- Biron‐Andreani C, Diaz‐Cau I, Ranc A, et al. Major surgery management in patients with haemophilia A and inhibitors on emicizumab prophylaxis without global coagulation monitoring. Br J Haematol. 2020;189(3):e100–e103. doi:10.1111/bjh.16512.
- Müller J, Pekrul I, Pötzsch B, Berning B, Oldenburg J, Spannagl M. Laboratory monitoring in emicizumab-treated persons with hemophilia A. Thromb Haemost. 2019;119(9):1384–1393. doi:10.1055/s-0039-1692427.
- Nougier C, Jeanpierre E, Ternisien C, et al. Emicizumab treatment: impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals). Eur J Haematol. 2020;105(6):675–681. doi:10.1111/ejh.13490.
- Yada K, Nogami K, Ogiwara K, et al. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis. Int J Hematol. 2019;110(4):419–430. doi:10.1007/s12185-019-02698-8.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 34, 2021 - Issue 2
Research Article
What proceduralists need to know about emicizumab for patients with hemophilia A
Evan G. Pivalizzaa Department of Anesthesiology, UTHealth McGovern Medical School, Houston, TexasCorrespondence[email protected]
https://orcid.org/0000-0002-2543-2075
, MBChBhttps://orcid.org/0000-0002-2543-2075 & , MD